These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 16702163)

  • 1. Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs.
    Niho S; Goto K; Yoh K; Kim YH; Ohmatsu H; Kubota K; Saijo N; Nishiwaki Y
    Jpn J Clin Oncol; 2006 May; 36(5):269-73. PubMed ID: 16702163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of preexisting pulmonary fibrosis detected on chest radiograph and CT on the development of gefitinib-related interstitial lung disease.
    Naito Y; Tsuchiya S; Ishihara S; Minato K; Shitara Y; Takise A; Suga T; Mogi A; Yamabe K; Saito R
    Am J Clin Oncol; 2008 Aug; 31(4):340-4. PubMed ID: 18845992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).
    Tammaro KA; Baldwin PD; Lundberg AS
    J Oncol Pharm Pract; 2005 Sep; 11(3):127-30. PubMed ID: 16390601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group.
    Endo M; Johkoh T; Kimura K; Yamamoto N
    Lung Cancer; 2006 May; 52(2):135-40. PubMed ID: 16574271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.
    Makris D; Scherpereel A; Copin MC; Colin G; Brun L; Lafitte JJ; Marquette CH
    BMC Cancer; 2007 Aug; 7():150. PubMed ID: 17683587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience.
    Hotta K; Kiura K; Takigawa N; Yoshioka H; Harita S; Kuyama S; Yonei T; Fujiwara K; Maeda T; Aoe K; Ueoka H; Kamei H; Umemura S; Moritaka T; Segawa Y; Kawai H; Bessho A; Kato K; Tabata M; Tanimoto M
    J Thorac Oncol; 2010 Feb; 5(2):179-84. PubMed ID: 20101144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between baseline pulmonary status and interstitial lung disease in patients with non-small-cell lung cancer treated with erlotinib--a cohort study.
    Johkoh T; Sakai F; Kusumoto M; Arakawa H; Harada R; Ueda M; Kudoh S; Fukuoka M
    Clin Lung Cancer; 2014 Nov; 15(6):448-54. PubMed ID: 25043209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.
    Ando M; Okamoto I; Yamamoto N; Takeda K; Tamura K; Seto T; Ariyoshi Y; Fukuoka M
    J Clin Oncol; 2006 Jun; 24(16):2549-56. PubMed ID: 16735708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging patterns and prognosis of patients with gefitinib-related interstitial lung disease.
    Yuan MK; Chang CY; Chang SC; Chang SJ; Tang GJ; Wei YF; Liu YC; Chen CY; Yu CJ
    Int J Clin Pharmacol Ther; 2011 Oct; 49(10):587-93. PubMed ID: 21961483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crizotinib Associated with Ground-Glass Opacity Predominant Pattern Interstitial Lung Disease: A Retrospective Observational Cohort Study with a Systematic Literature Review.
    Créquit P; Wislez M; Fleury Feith J; Rozensztajn N; Jabot L; Friard S; Lavole A; Gounant V; Fillon J; Antoine M; Cadranel J
    J Thorac Oncol; 2015 Aug; 10(8):1148-55. PubMed ID: 26200268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer.
    Yoneda KY; Shelton DK; Beckett LA; Gandara DR
    J Thorac Oncol; 2007 Jun; 2(6):537-43. PubMed ID: 17545850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer.
    Enomoto Y; Inui N; Kato T; Baba T; Karayama M; Nakamura Y; Ogura T; Suda T
    Lung Cancer; 2016 Jun; 96():63-7. PubMed ID: 27133752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis.
    Um SJ; Lee SK; Yang DK; Son C; Roh MS; Kim KN; Lee KN; Choi PJ
    Clin Respir J; 2009 Jul; 3(3):181-4. PubMed ID: 20298401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma.
    Wang KF; Chang CY; Chang SC; Liu YC; Yuan MK; Yang YH
    J Chin Med Assoc; 2013 Mar; 76(3):173-5. PubMed ID: 23497972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interstitial lung disease associated with gefitinib.
    Kataoka K; Taniguchi H; Hasegawa Y; Kondoh Y; Kimura T; Nishiyama O; Imaizumi K; Kawabe T; Kume H; Shimokata K
    Respir Med; 2006 Apr; 100(4):698-704. PubMed ID: 16137874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study.
    Kudoh S; Kato H; Nishiwaki Y; Fukuoka M; Nakata K; Ichinose Y; Tsuboi M; Yokota S; Nakagawa K; Suga M; ; Jiang H; Itoh Y; Armour A; Watkins C; Higenbottam T; Nyberg F
    Am J Respir Crit Care Med; 2008 Jun; 177(12):1348-57. PubMed ID: 18337594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight.
    Min JH; Lee HY; Lim H; Ahn MJ; Park K; Chung MP; Lee KS
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1099-109. PubMed ID: 21913033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erlotinib-induced acute interstitial lung disease associated with extreme elevation of the plasma concentration in an elderly non-small-cell lung cancer patient.
    Tsubata Y; Hamada A; Sutani A; Isobe T
    J Cancer Res Ther; 2012; 8(1):154-6. PubMed ID: 22531540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary toxicity associated with erlotinib.
    Liu V; White DA; Zakowski MF; Travis W; Kris MG; Ginsberg MS; Miller VA; Azzoli CG
    Chest; 2007 Sep; 132(3):1042-4. PubMed ID: 17873198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405).
    Akamatsu H; Inoue A; Mitsudomi T; Kobayashi K; Nakagawa K; Mori K; Nukiwa T; Nakanishi Y; Yamamoto N
    Jpn J Clin Oncol; 2013 Jun; 43(6):664-8. PubMed ID: 23585689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.